US5283342A
(en)
*
|
1992-06-09 |
1994-02-01 |
Neorx Corporation |
Biotinylated small molecules
|
US6075010A
(en)
*
|
1992-06-09 |
2000-06-13 |
Neorx Corporation |
Small molecular weight ligand-hexose containing clearing agents
|
US6416738B1
(en)
|
1973-12-07 |
2002-07-09 |
Neorx Corporation |
Pretargeting methods and compounds
|
US5556982A
(en)
*
|
1985-01-14 |
1996-09-17 |
Neorx Corporation |
Metal radionuclide labeled proteins for diagnosis and therapy
|
US5525338A
(en)
*
|
1992-08-21 |
1996-06-11 |
Immunomedics, Inc. |
Detection and therapy of lesions with biotin/avidin conjugates
|
FR2604092B1
(fr)
*
|
1986-09-19 |
1990-04-13 |
Immunotech Sa |
Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
|
US5420105A
(en)
*
|
1988-09-23 |
1995-05-30 |
Gustavson; Linda M. |
Polymeric carriers for non-covalent drug conjugation
|
ATE233100T1
(de)
*
|
1989-08-02 |
2003-03-15 |
Mitra Medical Technology Ab |
System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung
|
FR2652004B1
(fr)
*
|
1989-09-21 |
1994-10-28 |
Immunotech Partners |
Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
|
US5527528A
(en)
*
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
US5620689A
(en)
*
|
1989-10-20 |
1997-04-15 |
Sequus Pharmaceuuticals, Inc. |
Liposomes for treatment of B-cell and T-cell disorders
|
US5130129A
(en)
*
|
1990-03-06 |
1992-07-14 |
The Regents Of The University Of California |
Method for enhancing antibody transport through capillary barriers
|
DK176290D0
(da)
*
|
1990-07-24 |
1990-07-24 |
Novo Nordisk As |
Terapeutisk og diagnostisk praeparat
|
DE4025788C2
(de)
*
|
1990-08-10 |
1994-04-14 |
Diagnostikforschung Inst |
Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung sowie deren Verwendung in Diagnostik und Therapie
|
US5684137A
(en)
*
|
1990-09-28 |
1997-11-04 |
Neorx Corporation |
S3 N chelating compounds for the radiolabeling of ligands, anti-ligands or other proteins
|
US5733523A
(en)
*
|
1990-12-10 |
1998-03-31 |
Akzo Nobel N.V. |
Targeted delivery of a therapeutic entity using complementary oligonucleotides
|
IT1245748B
(it)
*
|
1990-12-21 |
1994-10-14 |
Mini Ricerca Scient Tecnolog |
Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
|
SE9100142L
(sv)
|
1991-01-17 |
1992-07-18 |
Bengt Sandberg |
En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
|
US6287792B1
(en)
*
|
1991-06-17 |
2001-09-11 |
The Regents Of The University Of California |
Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
|
US5326778A
(en)
*
|
1992-03-03 |
1994-07-05 |
Research Corporation Technologies, Inc. |
Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
|
JPH07507804A
(ja)
*
|
1992-06-09 |
1995-08-31 |
ネオルックス コーポレーション |
予備標的化方法及び化合物
|
US5976535A
(en)
*
|
1992-06-09 |
1999-11-02 |
Neorx Corporation |
Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
|
US6217869B1
(en)
|
1992-06-09 |
2001-04-17 |
Neorx Corporation |
Pretargeting methods and compounds
|
US5541287A
(en)
*
|
1992-06-09 |
1996-07-30 |
Neorx Corporation |
Pretargeting methods and compounds
|
US5624896A
(en)
*
|
1992-06-09 |
1997-04-29 |
Neorx Corporation |
Clearing agents useful in pretargeting methods
|
US6022966A
(en)
*
|
1993-11-22 |
2000-02-08 |
Neorx Corporation |
Pretargeting methods and compounds
|
US5578287A
(en)
*
|
1992-06-09 |
1996-11-26 |
Neorx Corporation |
Three-step pretargeting methods using improved biotin-active agent
|
US6358490B2
(en)
|
1992-06-09 |
2002-03-19 |
Neorx Corporation |
Three-step pretargeting methods and compounds
|
US5616690A
(en)
*
|
1992-06-09 |
1997-04-01 |
Neorx Corporation |
Hexose derivatized human serum albumin clearing agents
|
US5914312A
(en)
*
|
1992-06-09 |
1999-06-22 |
Neorx Corporation |
Pretargeting methods and compounds
|
US5911969A
(en)
|
1992-06-09 |
1999-06-15 |
Neorx Corporation |
Pretargeting protocols for enhanced localization of active agents to target sites
|
US6228362B1
(en)
|
1992-08-21 |
2001-05-08 |
Immunomedics, Inc. |
Boron neutron capture therapy using pre-targeting methods
|
US5846741A
(en)
*
|
1992-08-21 |
1998-12-08 |
Immunomedics, Inc. |
Boron neutron capture therapy using pre-targeting methods
|
GB2289679B
(en)
*
|
1993-01-15 |
1997-02-05 |
Imp Cancer Res Tech |
Compounds comprising a target cell-specific portion and a portion which has DNA endonucleolytic activity, and uses thereof
|
GB9300686D0
(en)
*
|
1993-01-15 |
1993-03-03 |
Imp Cancer Res Tech |
Compounds for targeting
|
IL108388A0
(en)
*
|
1993-01-21 |
1994-04-12 |
Harvard College |
Amplified direction of effector groups to specific target cells in an animal
|
CA2154896A1
(en)
*
|
1993-01-28 |
1994-08-04 |
Robert Allen Snow |
Immunoreactive reagents employing heterodimers
|
WO1994016729A1
(en)
*
|
1993-01-28 |
1994-08-04 |
Neorx Corporation |
Targeted nitric oxide pathway or nitric oxide synthase modulation
|
CA2154667A1
(en)
*
|
1993-02-02 |
1994-08-18 |
Linda M. Gustavson |
Directed biodistribution of small molecules
|
US7713528B1
(en)
|
1993-02-18 |
2010-05-11 |
Enzo Therapeutics, Inc. |
Method for in vivo delivery of active compounds using reagent conjugate
|
JPH08512019A
(ja)
*
|
1993-03-10 |
1996-12-17 |
ザ・ウエルカム・ファウンデーション・リミテッド |
免疫反応剤およびキレート化された放射性核種からなるl−エナンチオメリックオリゴヌクレオチド複合体を用いる腫瘍ターゲッティング
|
US5482698A
(en)
*
|
1993-04-22 |
1996-01-09 |
Immunomedics, Inc. |
Detection and therapy of lesions with biotin/avidin polymer conjugates
|
KR100220864B1
(ko)
*
|
1993-05-17 |
1999-09-15 |
오트리브 데이비스 더블유 |
비오틴/아비딘-금속 단백질 콘쥬게이트로 병변을 검출 및 치료하기 위한 조성물
|
US6120768A
(en)
*
|
1993-05-17 |
2000-09-19 |
Immunomedics, Inc. |
Dota-biotin derivatives
|
JPH09501147A
(ja)
*
|
1993-06-07 |
1997-02-04 |
ザ・ウエルカム・ファウンデーション・リミテッド |
モノアミンオキシダーゼを使用する免疫反応性試薬
|
EP0650735A3
(de)
*
|
1993-07-09 |
1999-04-14 |
Akzo Nobel N.V. |
Kit und Verfahren zum Vorziehen
|
CA2165538A1
(en)
*
|
1993-08-17 |
1995-02-23 |
Sudhakar Kasina |
S3n chelating compounds for the radiolabeling of ligands, anti-ligands or other proteins
|
KR100361933B1
(ko)
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
US6015897A
(en)
*
|
1993-12-07 |
2000-01-18 |
Neorx Corporation |
Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
|
CA2178477A1
(en)
*
|
1993-12-07 |
1995-06-15 |
Louis J. Theodore |
Pretargeting methods and compounds
|
JPH09506594A
(ja)
*
|
1993-12-07 |
1997-06-30 |
ネオルクス コーポレーション |
プレターゲティング方法及び化合物
|
IL112372A
(en)
*
|
1994-02-07 |
2001-08-26 |
Res Dev Foundation |
Non-viral vector for the delivery of genetic information to cells
|
CA2190727C
(en)
*
|
1994-05-19 |
2006-07-18 |
Sudhakar Kasina |
Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
|
US5716594A
(en)
*
|
1994-06-06 |
1998-02-10 |
The Jmde Trust |
Biotin compounds for targetting tumors and sites of infection
|
DE4428056A1
(de)
*
|
1994-07-29 |
1996-02-08 |
Schering Ag |
Verwendung von Mikropartikelpräparationen zur Eliminierung gelöster, nicht nierengängiger Substanzen aus dem Blut
|
US5670132A
(en)
*
|
1994-09-20 |
1997-09-23 |
Immunomedics, Inc. |
Modified radioantibody fragments for reduced renal uptake
|
US6908903B1
(en)
|
1994-12-07 |
2005-06-21 |
Aletheon Pharmaceuticals, Inc. |
Cluster clearing agents
|
US6172045B1
(en)
|
1994-12-07 |
2001-01-09 |
Neorx Corporation |
Cluster clearing agents
|
DE19503664C2
(de)
*
|
1995-01-27 |
1998-04-02 |
Schering Ag |
Magnetorelaxometrische Detektion von Analyten
|
US5955605A
(en)
*
|
1995-02-21 |
1999-09-21 |
Neorx Corporation |
Biotinidase resistant biotin-DOTA conjugates
|
US5846537A
(en)
*
|
1995-06-07 |
1998-12-08 |
University Of Rochester |
Modified avidin and streptavidin and methods of use thereof
|
CA2223261C
(en)
*
|
1995-06-07 |
2010-05-11 |
Immunomedics, Inc. |
Improved delivery of diagnostic and therapeutic agents to a target site
|
US5780010A
(en)
*
|
1995-06-08 |
1998-07-14 |
Barnes-Jewish Hospital |
Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
|
US6821506B2
(en)
|
1995-06-08 |
2004-11-23 |
Barnes-Jewish Hospital |
Site specific binding system, imaging compositions and methods
|
US6548046B1
(en)
|
1995-06-08 |
2003-04-15 |
Barnes-Jewish Hospital |
Site specific binding system, imaging compositions and methods
|
US5958371A
(en)
*
|
1995-06-08 |
1999-09-28 |
Barnes-Jewish Hospital |
Site specific binding system, nuclear imaging compositions and methods
|
DE19646762B4
(de)
*
|
1996-11-04 |
2004-05-13 |
Schering Ag |
Verwendung von Metallverbindungen zur Herstellung von Mitteln zur Strahlentherapie von Tumoren
|
US6005083A
(en)
|
1997-03-28 |
1999-12-21 |
Neorx Corporation |
Bridged aromatic substituted amine ligands with donor atoms
|
US6432699B1
(en)
|
1997-03-28 |
2002-08-13 |
New York University |
Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
|
US7405320B2
(en)
|
1998-06-22 |
2008-07-29 |
Immunomedics, Inc. |
Therapeutic and diagnostic conjugates for use with multispecific antibodies
|
CA2335364C
(en)
*
|
1998-06-22 |
2010-05-04 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
US6962702B2
(en)
*
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US7138103B2
(en)
*
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
US7833528B2
(en)
*
|
1998-06-22 |
2010-11-16 |
Immunomedics, Inc. |
Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
|
US7387772B1
(en)
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
US6458953B1
(en)
*
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
AU2610000A
(en)
|
1999-01-12 |
2000-08-01 |
Cambridge University Technical Services Limited |
Compounds and methods to inhibit or augment an inflammatory response
|
AU2004202725B2
(en)
*
|
1999-05-25 |
2006-12-21 |
Barnes-Jewish Hospital |
Site specific binding system, nuclear imaging compositions and methods
|
AU5905400A
(en)
|
1999-07-14 |
2001-02-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions for delivery and retention of active agents to lymph nodes
|
US7220401B2
(en)
|
1999-09-24 |
2007-05-22 |
Barnes-Jewish Hospital |
Blood clot-targeted nanoparticles
|
WO2001025399A2
(en)
*
|
1999-10-04 |
2001-04-12 |
Vion Pharmaceuticals, Inc. |
Non-invasive tumor imaging by tumor-targeted bacteria
|
IT1317835B1
(it)
|
2000-02-15 |
2003-07-15 |
San Raffaele Centro Fond |
Citochine modificate per uso nella terapia del cancro.
|
US7309694B2
(en)
|
2000-02-15 |
2007-12-18 |
Fondazione Centro San Raffaele Del Monte Tabor |
Modified cytokines for use in cancer therapy
|
US7109303B2
(en)
|
2000-02-15 |
2006-09-19 |
Fondazione Centro San Raffaele Del Monte Tabor |
Modified cytokines for use in cancer therapy
|
US20040002068A1
(en)
*
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
WO2001082871A2
(en)
*
|
2000-05-04 |
2001-11-08 |
Ambryx Biotechnology, Inc. |
Method of using zinc isotope for therapy and diagnosis of colon cancer
|
US6951939B2
(en)
*
|
2000-06-08 |
2005-10-04 |
La Jolla Pharmaceutical Company |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
US7179449B2
(en)
*
|
2001-01-30 |
2007-02-20 |
Barnes-Jewish Hospital |
Enhanced ultrasound detection with temperature-dependent contrast agents
|
WO2002078638A2
(en)
*
|
2001-03-30 |
2002-10-10 |
University Of Massachusetts |
Morpholino imaging and therapy
|
AU2002315411A1
(en)
*
|
2001-06-21 |
2003-01-08 |
Glycotech Corporation |
Detection and treatment of prostate cancer
|
US7311892B2
(en)
*
|
2001-10-26 |
2007-12-25 |
The Uab Research Foundation |
Multidrug multiligand conjugates for targeted drug delivery
|
GB0209896D0
(en)
|
2002-04-30 |
2002-06-05 |
Molmed Spa |
Conjugate
|
US7534431B2
(en)
|
2003-01-31 |
2009-05-19 |
Immunomedics, Inc. |
Methods and compositions for administering therapeutic and diagnostic agents
|
JP3931818B2
(ja)
*
|
2003-02-13 |
2007-06-20 |
株式会社デンソー |
車両用空調装置
|
ITRM20030196A1
(it)
*
|
2003-04-24 |
2004-10-25 |
Sigma Tau Ind Farmaceuti |
Uso di reagenti per la preparazione di un medicamento
|
WO2005021494A2
(en)
*
|
2003-06-13 |
2005-03-10 |
Immunomedics, Inc. |
D-amino acid peptides
|
ITMI20040187A1
(it)
*
|
2004-02-06 |
2004-05-06 |
Cosmo Spa |
Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
|
WO2006094192A2
(en)
|
2005-03-03 |
2006-09-08 |
Immunomedics, Inc. |
Humanized l243 antibodies
|
US20090035257A1
(en)
*
|
2005-08-25 |
2009-02-05 |
Repair Technologies, Inc. |
Devices, compositions and methods for the protection and repair of cells and tissues
|
EP2674440B1
(de)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Polyvalente bioaktive anordnungen auf immunglobulinbasis
|
US20070280418A1
(en)
*
|
2006-06-05 |
2007-12-06 |
Sirius Medicine, Llc |
Coupled Carriers for Enhancing Therapy
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
EP2478110B1
(de)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Klasse-i-anti-cea-antikörper und verwendungen davon
|
WO2011068845A1
(en)
|
2009-12-02 |
2011-06-09 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
EP2704751B1
(de)
|
2011-05-02 |
2019-04-17 |
Immunomedics, Inc. |
Ultrafiltrationskonzentration ausgewählter allotypen-antikörper für kleinvolumige verabreichung
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
US9840566B2
(en)
*
|
2013-11-21 |
2017-12-12 |
Apeiron Biologics Ag |
Preparations and methods for treating a GD2 positive cancer
|
ES2768649T3
(es)
|
2013-11-21 |
2020-06-23 |
Apeiron Biologics Ag |
Preparaciones para tratar un cáncer positivo para GD2
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
EP3316885B1
(de)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
|